investigated the impact on OS of the nivolumab + cetuximab combination in patients with R/M HNSCC following the evidence about the release of interferon (IFN)-gamma and chemokines from natural killer (NK) cells after binding cetuximab to EGFR with the subsequent increase of PD-L1. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.